Evidence map›Paper›PMID 29058292›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2017

Danshen modulates Nrf2-mediated signaling pathway in cisplatin-induced renal injury.

Si-Si Cao, Miao Yan, Zhen-Yan Hou, Ying Chen, Yun-Sheng Jiang, Xin-Rong Fan, Ping-Fei Fang, Bi-Kui Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Screening of rosmarinic acid fromPharmaceutical biology · 2023
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Si-Si CaoDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Miao YanDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhen-Yan HouDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Ying ChenDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yun-Sheng JiangDepartment of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xin-Rong FanInstitute of Basic Theories of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Ping-Fei FangDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Bi-Kui ZhangDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China. zhbk68@163.com.
Central South University · CNSecond Xiangya Hospital of Central South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Danshen, an efficacious agent for cardiovascular diseases, has been found to play an essential role in kidney injury. In the present study, the effect of Danshen on cisplatin-induced renal dysfunction was investigated in a mouse model. Danshen was administered to mice at a dose of 3 g/kg 4 days before and 3 days after cisplatin treatment. A single intraperitoneal injection of 20 mg/kg cisplatin was used to induce nephrotoxicity. The mice were sacrificed 72 h after cisplatin intoxication. Biochemical parameters including serum creatinine and blood urea nitrogen were analyzed. Histopathological changes of kidney tissues were detected using HE staining. Antioxidant enzymes (GSH-Px and SOD) and peroxidative product (MDA) were detected. Protein expressions of Nrf2 and its target genes including HO-1 and NQO1 were measured by Western blotting. The results showed that pretreatment with Danshen significantly reduced serum creatinine and blood urea nitrogen in the cisplatin-treated mice. Histopathological examination showed that Danshen mitigated the renal damage induced by cisplatin. Moreover, Danshen restored the activities of antioxidant enzymes (GSH-Px and SOD) and normalized the MDA contents in renal tissues. Western blotting revealed that Danshen enhanced the expressions of Nrf2 and its target genes in cisplatin-exposed mice. It was suggested that Danshen protects against the cisplatin-induced renal impairment in the mice, which is potentially associated with the upregulation of Nrf2-mediated signaling pathway.

Indexed as

Acute Kidney InjuryAnimalsBlood Urea NitrogenCisplatinCreatinineDisease Models, AnimalDrugs, Chinese HerbalGene Expression RegulationMaleMiceNF-E2-Related Factor 2Salvia miltiorrhizaSignal TransductionCisplatinCreatininedan-shen root extractDrugs, Chinese HerbalNfe2l2 protein, mouseNF-E2-Related Factor 2cisplatinDanshennephrotoxicityNrf2oxidative stress

Identifiers

PMID29058292
OpenAlexW2769277866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.